Akorn (AKRX) Announces FDA Okay for Ofloxacin Ophthalmic Solution USP
More News related to AKRX
- Akorn (AKRX) Posts Q3 Loss of $0.06, Beats By 2c
- Akorn Reports Third Quarter 2009 Financial Results; Launches Two New Products: Ketorolac Tromethamine Ophthalmic and Hydralazine HCL
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
- Akorn (AKRX) Files Shelf Offering of Up To 13.3M Shares
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Akorn, Inc. (NASDAQ: AKRX) announced that the FDA has granted approval for Akorn’s Abbreviated New Drug Application for Ofloxacin Ophthalmic Solution USP, 0.3%.
Ofloxacin Ophthalmic Solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers. Annual sales for Ofloxacin were approximately $7.5 million in 2007, according to IMS sales data. [LJ]
Related Categories
FDAStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
